Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With Pegcetacoplan

NCT04729062 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04729062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04729062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With Pegcetacoplan
Lead sponsor
Apellis Pharmaceuticals, Inc.
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulonephritis, c3 glomerulopathy, c3g, complement 3 glomerulonephritis, complement 3 glomerulopathy, complement 3 glomerulopathy (c3g), ddd, dense deposit disease, ic-mpgn, immune complex membranoproliferative glomerulonephritis (ic-mpgn), membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis (mpgn)